Updated:
Ecphora Capital Management Company
Ecphora Capital is a medtech-focused venture firm operating out of Baltimore, where Managing Partner Deborah Hemingway has built a proprietary,...
Ecphora Capital Management Company
Ecphora Capital is a medtech-focused venture firm operating out of Baltimore, where Managing Partner Deborah Hemingway has built a proprietary, data-driven startup evaluation program based on over 20 years of entrepreneurial research. The program assesses prospective portfolio companies on product-market fit, technical feasibility, IP landscape, and exit feasibility over a three-month diligence period. The firm targets medical devices, biotech, digital health, and broader healthtech sectors, concentrating on companies emerging from what it calls the BioHealth Capital Region. Ecphora secures deal flow through strategic partnerships with anchor institutions including Johns Hopkins University, the University of Maryland system, the National Institutes of Health, and the National Institute of Standards and Technology. Its relationship with The LaunchPort, a Baltimore-based medical device manufacturing accelerator, provides exclusive first-look access to ventures transitioning from concept to commercialization. The firm runs a quarterly seminar series for portfolio-company CEOs and operates SPV Concierge Services, an in-house capability that administers special-purpose vehicles for startups throughout their lifecycle. Managing Director Jeremy Neilson brings operational depth, having administered over $12B in assets across thousands of SPVs. The team includes several venture partners and a director of investor relations, supporting Hemingway in sourcing and supporting companies across the Maryland-DC-Virginia corridor. Hemingway has been involved in founding, funding, and serving on the boards of 53 startups. Ecphora's structure as a solo-GP-led firm anchored to a dense institutional research cluster is its structural differentiator. Rather than competing for broadly auctioned deals, it operates as a funnel for medical innovation originating inside the laboratories of Johns Hopkins and University of Maryland investigators — a model that resembles technology-transfer seeding more than traditional venture capital.
General information
Firm type
Private Equity
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Baltimore
Corporate office
101 W Dickman St, Suite 900, Baltimore, MD 21230, United States
Principals
Deborah Hemingway
Managing Partner
Jeremy Neilson
Managing Director, Head of Operations
Charles Kirby
Venture Partner
Sathya Janardhanan
Venture Partner
Lauren Renz
Director of Investor Relations
Camilo Vanegas
Venture Partner
Sector focus
Frequently asked questions
Who runs investment decisions at Ecphora Capital?
Managing Partner Deborah Hemingway, PhD, leads investment decisions. She is a biophysicist by training and operates as a solo general partner. An extended team of venture partners and a managing director for operations support sourcing, diligence, and portfolio management.
How does Ecphora Capital source proprietary deal flow?
Ecphora relies on exclusive institutional partnerships in the BioHealth Capital Region. It holds first-look access through The LaunchPort medical device accelerator and maintains structured relationships with Johns Hopkins University, the University of Maryland system, the NIH, and NIST. This funnel gives the firm early visibility into medtech innovations emerging from federally funded and academic laboratories.
Does Ecphora Capital participate in fund commitments or only direct deals?
Ecphora makes direct early-stage investments in medtech startups. It also operates SPV Concierge Services, which structures and administers special-purpose vehicles for portfolio companies and external syndicates, but the firm itself deploys capital through its own direct investment vehicle.
What is Ecphora Capital's known posture on co-investments alongside external GPs?
The firm's SPV Concierge operation suggests it is comfortable syndicating deals with other investors. However, Ecphora's public materials do not detail a formal co-investment program. Its primary posture appears to be leading or co-leading early-stage medtech rounds in the Mid-Atlantic ecosystem.
Which sectors does Ecphora Capital explicitly avoid?
Ecphora's stated focus is exclusively medical: medical devices, biotech, digital health, and healthtech. It does not target enterprise software, fintech, consumer, or industrials, and its public positioning implies no intention to branch outside life sciences.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: